11月19日上午盘中交易时段，荣昌生物(09995.HK)股价出现大幅上涨,涨幅达到5.53%。市场分析人士指出,机构预期看好该公司前景是主要推动力。
数据显示,在所有20家参与评级的机构中,有80%的券商给予荣昌生物买入评级,20%的券商给予持有评级。这表明绝大多数机构认为该股长期前景向好,未来股价有上涨空间。投资者对公司业绩前景抱有较高预期,使得盘中资金呈现小幅净流入态势。
不过也有分析人士提醒,尽管公司最新财报中营收规模达到13.41亿港元,但仍然处于亏损状态,净利润为-11.88亿港元。投资者需要保持谨慎态度,关注公司盈利能力是否存在持续改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.